Article

From ASCO: Updates on the Afinitor BOLERO-3 study in breast cancer

Author(s):

Debu Tripathy

Debu Tripathy blog image

Debu Tripathy, MD, editor-in-chief of CURE, discusses the BOLERO-3 study, which combines the mTOR inhibitor, everolimus, with Herceptin (trastuzumab) and chemotherapy in patients whose cancers progressed on previous treatment. This study was presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.

Related Videos
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of woman.
Image of woman.
Image of woman.
Image of woman.
Image of man wearing baseball cap backwards.
Image of smiling doctor.
Related Content
Image of lung.
March 31st 2025

COCOON Trial Regimen Reduces Dermatologic Side Effects in Mutated Lung Cancer

Spencer Feldman
The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 trial data showed.
The Importance of Spotting Endometrial Cancer
March 18th 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Karen Cohn is a retired middle school special education teacher who was diagnosed with follicular lymphoma in July 2020. Catch up on all of Karen's blogs here!
March 31st 2025

The Positivity Trap of Follicular Lymphoma and Cancer

Karen Cohn
As a lymphoma survivor, I struggle with the positivity trap — sometimes, I just want my fears validated instead of being reassured everything is fine.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Ovaries.
March 31st 2025

Relacorilant Plus Chemo Meets Primary Goal in Ovarian Cancer Trial

Spencer Feldman
The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ovarian cancer.
Illustration of stomach.
March 31st 2025

Inside the Mind of a Bile Duct Cancer Survivor

Lisa Craine
I’ve spent 14 years navigating recovery, mental health challenges and giving back to the cancer community through patient mentorship.